Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):810-822. doi: 10.2215/CJN.12901018. Epub 2019 Apr 22.

Abstract

Background and objectives: Whether prolonged dual antiplatelet therapy (DAPT) is more protective in patients with CKD and drug-eluting stents compared with shorter DAPT is uncertain. The purpose of this meta-analysis was to examine whether shorter DAPT in patients with drug-eluting stents and CKD is associated with lower mortality or major adverse cardiovascular event rates compared with longer DAPT.

Design, setting, participants, & measurements: A Medline literature research was conducted to identify randomized trials in patients with drug-eluting stents comparing different DAPT duration strategies. Inclusion of patients with CKD was also required. The primary outcome was a composite of all-cause mortality, myocardial infarction, stroke, or stent thrombosis (definite or probable). Major bleeding was the secondary outcome. The risk ratio (RR) was estimated using a random-effects model.

Results: Five randomized trials were included (1902 patients with CKD). Short DAPT (≤6 months) was associated with a similar incidence of the primary outcome, compared with 12-month DAPT among patients with CKD (48 versus 50 events; RR, 0.93; 95% confidence interval [95% CI], 0.64 to 1.36; P=0.72). Twelve-month DAPT was also associated with a similar incidence of the primary outcome compared with extended DAPT (≥30 months) in the CKD subgroup (35 versus 35 events; RR, 1.04; 95% CI, 0.67 to 1.62; P=0.87). Numerically lower major bleeding event rates were detected with shorter versus 12-month DAPT (9 versus 13 events; RR, 0.69; 95% CI, 0.30 to 1.60; P=0.39) and 12-month versus extended DAPT (9 versus 12 events; RR, 0.83; 95% CI, 0.35 to 1.93; P=0.66) in patients with CKD.

Conclusions: Short DAPT does not appear to be inferior to longer DAPT in patients with CKD and drug-eluting stents. Because of imprecision in estimates (few events and wide confidence intervals), no definite conclusions can be drawn with respect to stent thrombosis.

Keywords: Drug-Eluting Stents; Hemorrhage; Incidence; Myocardial Infarction; Odds Ratio; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk; Stroke; all-cause mortality; chronic kidney disease; drug-eluting stents; major bleeding; myocardial infarction; thrombosis.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Coronary Disease / complications
  • Coronary Disease / therapy*
  • Drug Therapy, Combination
  • Drug-Eluting Stents*
  • Hemorrhage / chemically induced
  • Humans
  • Myocardial Infarction / prevention & control
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / adverse effects
  • Prosthesis Failure
  • Randomized Controlled Trials as Topic
  • Renal Insufficiency, Chronic / complications*
  • Stroke / prevention & control
  • Thrombosis / prevention & control
  • Time Factors

Substances

  • Platelet Aggregation Inhibitors